Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  TiGenix NV    TIG   BE0003864817

TIGENIX NV (TIG)
My previous session
Most popular
  Report  
 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Financials (EUR)
Sales 2018 29,7 M
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
Sales 2019 -
EBIT 2019 -
Net income 2019 -
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019 -
Capi. / Sales2018 17,6x
Capi. / Sales2019 -
Capitalization 523 M
More Financials
Company
TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products.The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells.It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction,... 
More about the company
Latest news on TIGENIX NV
08/04TIGENIX : Takeda finalises buyout of TiGenix
AQ
08/03TAKEDA PHARMACEUTICAL : Completes its Acquisition of TiGenix Following Expiratio..
AQ
08/03TAKEDA PHARMACEUTICAL : closes TiGenix acquisition for about $608m
AQ
07/31TIGENIX : Takeda Completes its Acquisition of TiGenix Following Expiration of th..
PU
07/31TIGENIX : Takeda Completes its Acquisition of TiGenix Following Expiration of th..
GL
07/23TIGENIX : Transparency notification pursuant to Article 14 of the Law of May 2,..
GL
07/10TAKEDA PHARMACEUTICAL : and TiGenix Announce Results of Second Acceptance Period..
AQ
07/09TIGENIX : Transparency Information
AQ
07/07TIGENIX : Takeda and TiGenix Announce Results of Second Acceptance Period for th..
AQ
07/06TIGENIX : Takeda and TiGenix Announce Results of Second Acceptance Period for th..
PU
More news
Sector news : Bio Therapeutic Drugs
10/21Roche takes on Loxo, Bayer in gene-defined cancer class
RE
10/19FDA Approves Asthma Indication for Regeneron and Sanofi's Dupixent
DJ
10/16Sanofi's Dupixent Shows Positive Headline Results in Two Phase 3 Studies
DJ
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
04/12Tigenix Sa reports FY results 
01/31BONE THERAPEUTICS : In (Re)Search For Money 
01/12Takeda's Offer On Tigenix - Good Deal Or Not? 
2017TIGENIX : This Stem Cell Pioneer Is Up 40% Since IPO With More Upside To Come 
2017Tigenix Sa reports FY results 
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price -
Spread / Average Target -100%
EPS Revisions
Managers
NameTitle
Jean Stéphenne Chairman
Claudia D'Augusta Chief Financial Officer & Compliance Officer
Wilfried Dalemans Chief Technical Officer
Marie Paule Richard Chief Medical Officer
Willy W. Duron Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
TIGENIX NV82.72%0
GILEAD SCIENCES1.59%96 150
VERTEX PHARMACEUTICALS20.99%45 720
REGENERON PHARMACEUTICALS2.18%41 951
NEUROCRINE BIOSCIENCES, INC.41.84%10 366
SAREPTA THERAPEUTICS INC136.05%9 222